SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a strong financial performance with a 25% revenue increase, improved gross margins, and a shift from net loss to net income. The positive cash flow indicates solid financial health. Despite the absence of strategic and operational updates, the financial metrics suggest a positive outlook. However, the lack of strategic guidance and acknowledgment of risks tempers the sentiment slightly. The overall impact is likely positive, given the financial turnaround and margin improvements.
Key Financial Performance
Revenue Revenue for Q4 2025 was $12.5 million, representing a 25% increase year-over-year. This growth was driven by strong demand for our products in both domestic and international markets.
Gross Margin Gross margin improved to 55% in Q4 2025, up from 50% in the same period last year. The improvement was attributed to operational efficiencies and cost-saving initiatives.
Net Income Net income for Q4 2025 was $2.1 million, compared to a net loss of $0.5 million in Q4 2024. This turnaround was due to increased revenue and better cost management.
Operating Expenses Operating expenses were $4.8 million in Q4 2025, a 10% increase year-over-year. The rise was primarily due to higher R&D investments and marketing expenses.
Cash Flow Cash flow from operations was $3.2 million in Q4 2025, up from $1.8 million in Q4 2024, reflecting improved profitability and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges risks and uncertainties related to future financial results, production expectations, business development opportunities, and changes in tariff rates. These factors are beyond the company's control and could materially affect financial outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bauser ROTH
Byrnes Northland
CEO Chairman
CEO Morgan
CFO Secretary
Capital Llc
Capital Markets
Carl Byrnes
Cassel Intelligent
Chairman Peter
Division Ian
Division Kyle
EDT Hello
Fanatics Capital
Frank CEO
Hello today
Ian Cassel
Intelligent Fanatics
Kyle Bauser
Llc EDT
Markets Research
Morgan Frank
Peter Sorensen
Research Division
SANUWAVE Instructions
Secretary Carl
Sorensen CFO
meeting CEO
pleasure meeting
today SANUWAVE
SNWV Transcript
SANUWAVE Health, Inc. (SNWV) Q1 2026 Earnings Call Transcript
Unknown5-13
Despite a slight revenue increase and optimistic guidance, the company's financial health is concerning due to increased operating expenses, a decline in gross margin, and extended sales cycles. The Q&A reveals confidence in future growth but lacks specifics on product advancements and market expansion. The transition to wholesale pricing and sales tax exposure add further risk. Overall, the financial metrics and uncertainties suggest a negative stock price movement in the short term.
SANUWAVE Health, Inc. (SNWV) Q4 2025 Earnings Call Transcript
Positive3-27
The earnings call highlights a strong financial performance with a 25% revenue increase, improved gross margins, and a shift from net loss to net income. The positive cash flow indicates solid financial health. Despite the absence of strategic and operational updates, the financial metrics suggest a positive outlook. However, the lack of strategic guidance and acknowledgment of risks tempers the sentiment slightly. The overall impact is likely positive, given the financial turnaround and margin improvements.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call summary indicates a focus on cost efficiency, marketing expansion, and a conservative revenue guidance due to past anomalies. The Q&A section reveals positive sentiment towards sales strategies and potential growth, despite some uncertainties in adoption timelines. Key factors like improved financial footing and inbound interest from distributors suggest a positive outlook. However, the lack of international expansion and cautious revenue guidance temper expectations. Overall, the sentiment is positive, with a potential stock price increase of 2% to 8% over the next two weeks.
SANUWAVE Health, Inc. (SNWV) Q3 2025 Earnings Call Transcript
Unknown10-6
The earnings call reveals several negative aspects, including a miss on Q3 revenue guidance, market uncertainty impacting growth, and challenges in forecasting. Despite some positive developments like a record September revenue and improved sales pipeline, the downward adjustment of annual revenue guidance and regulatory risks weigh heavily. The Q&A section reflects cautious optimism but lacks specific details, and the refusal to provide detailed guidance further dampens sentiment. These factors suggest a likely stock price decline in the range of -2% to -8%.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
